LIFRENZAL

Dead / Abandoned — Abandoned — no statement of use filed (as of 22 Sept 2025)

What this means for you

This application is over — abandoned 22 Sept 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
97518240
Mark type
Stylized text
Filed
25 Jul 2022
Published for opposition
26 Dec 2023
Abandoned
22 Sept 2025
Attorney of record
Chelsea E. Carbone

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in the treatment of diseases and disorders in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in pediatric, geriatric, emergency, family, and human preventative medicine for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease; pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease
  • Class 042 — Scientific and technological services: Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of drug discovery process development, drug discovery validation, drug discovery qualification, and drug discovery manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation and testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation and testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

Owner

Prosecution history

  • 22 Sept 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
  • 22 Sept 2025 — ABANDONMENT - NO USE STATEMENT FILED
  • 15 Jul 2025 — ASSIGNED TO EXAMINER
  • 04 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 04 Feb 2025 — SOU EXTENSION 2 GRANTED
  • 03 Feb 2025 — SOU EXTENSION 2 FILED
  • 03 Feb 2025 — SOU TEAS EXTENSION RECEIVED
  • 02 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 02 Aug 2024 — SOU EXTENSION 1 GRANTED
  • 02 Aug 2024 — SOU EXTENSION 1 FILED
  • 02 Aug 2024 — SOU TEAS EXTENSION RECEIVED
  • 20 Feb 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 08 Jan 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 08 Jan 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 08 Jan 2024 — TEAS CHANGE OF OWNER ADDRESS RECEIVED

View this trademark record on Marksy